Your browser doesn't support javascript.
loading
Genetic coding variant in complement factor B (CFB) is associated with increased risk for perianal Crohn's disease and leads to impaired CFB cleavage and phagocytosis.
Akhlaghpour, Marzieh; Haritunians, Talin; More, Shyam K; Thomas, Lisa S; Stamps, Dalton T; Dube, Shishir; Li, Dalin; Yang, Shaohong; Landers, Carol J; Mengesha, Emebet; Hamade, Hussein; Murali, Ramachandran; Potdar, Alka A; Wolf, Andrea J; Botwin, Gregory J; Khrom, Michelle; Ananthakrishnan, Ashwin N; Faubion, William A; Jabri, Bana; Lira, Sergio A; Newberry, Rodney D; Sandler, Robert S; Sartor, R Balfour; Xavier, Ramnik J; Brant, Steven R; Cho, Judy H; Duerr, Richard H; Lazarev, Mark G; Rioux, John D; Schumm, L Philip; Silverberg, Mark S; Zaghiyan, Karen; Fleshner, Phillip; Melmed, Gil Y; Vasiliauskas, Eric A; Ha, Christina; Rabizadeh, Shervin; Syal, Gaurav; Bonthala, Nirupama N; Ziring, David A; Targan, Stephan R; Long, Millie D; McGovern, Dermot P B; Michelsen, Kathrin S.
Afiliação
  • Akhlaghpour M; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Haritunians T; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • More SK; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Thomas LS; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Stamps DT; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Dube S; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Li D; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Yang S; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Landers CJ; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Mengesha E; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Hamade H; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Murali R; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Potdar AA; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Wolf AJ; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Botwin GJ; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Khrom M; Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Ananthakrishnan AN; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Jabri B; Division of Gastroenterology, Massachusetts General Hospital, Boston, Massachusetts, USA.
  • Lira SA; Gastroenterology, Mayo Clinic, Rochester, Minnesota, USA.
  • Newberry RD; Biological Sciences Division, University of Chicago, Pritzker School of Medicine, Chicago, Illinois, USA.
  • Sandler RS; Immunology Institute, Mount Sinai Medical Center, New York, New York, USA.
  • Sartor RB; Division of Gastroenterology, Washington Univ. Sch. of Medicine, Saint Louis, Missouri, USA.
  • Xavier RJ; Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Brant SR; Center for Gastrointestinal Biology and Disease, University of North Carolina, Chapel Hill, North Carolina, USA.
  • Cho JH; Broad Institute Harvard, Cambridge, Massachusetts, USA.
  • Duerr RH; Rutgers Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA.
  • Lazarev MG; Genetics and Genomics Sciences, Mt Sinai School of Medicine, New York, New York, USA.
  • Rioux JD; Departments of Medicine and Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Schumm LP; Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Silverberg MS; Faculty of Medicine, Universite de Montreal, Montreal, Québec, Canada.
  • Zaghiyan K; Dept of Health Studies, University of Chicago, Chicago, Illinois, USA.
  • Fleshner P; Division of Gastroenterology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada.
  • Melmed GY; Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Vasiliauskas EA; Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Ha C; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Rabizadeh S; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Syal G; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Bonthala NN; Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Ziring DA; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Targan SR; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Long MD; Department of Pediatrics, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • McGovern DPB; F. Widjaja Inflammatory Bowel Disease Institute, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, California, USA.
  • Michelsen KS; Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Gut ; 72(11): 2068-2080, 2023 11.
Article em En | MEDLINE | ID: mdl-37080587
ABSTRACT

OBJECTIVE:

Perianal Crohn's disease (pCD) occurs in up to 40% of patients with CD and is associated with poor quality of life, limited treatment responses and poorly understood aetiology. We performed a genetic association study comparing CD subjects with and without perianal disease and subsequently performed functional follow-up studies for a pCD associated SNP in Complement Factor B (CFB).

DESIGN:

Immunochip-based meta-analysis on 4056 pCD and 11 088 patients with CD from three independent cohorts was performed. Serological and clinical variables were analysed by regression analyses. Risk allele of rs4151651 was introduced into human CFB plasmid by site-directed mutagenesis. Binding of recombinant G252 or S252 CFB to C3b and its cleavage was determined in cell-free assays. Macrophage phagocytosis in presence of recombinant CFB or serum from CFB risk, or protective CD or healthy subjects was assessed by flow cytometry.

RESULTS:

Perianal complications were associated with colonic involvement, OmpC and ASCA serology, and serology quartile sum score. We identified a genetic association for pCD (rs4151651), a non-synonymous SNP (G252S) in CFB, in all three cohorts. Recombinant S252 CFB had reduced binding to C3b, its cleavage was impaired, and complement-driven phagocytosis and cytokine secretion were reduced compared with G252 CFB. Serine 252 generates a de novo glycosylation site in CFB. Serum from homozygous risk patients displayed significantly decreased macrophage phagocytosis compared with non-risk serum.

CONCLUSION:

pCD-associated rs4151651 in CFB is a loss-of-function mutation that impairs its cleavage, activation of alternative complement pathway, and pathogen phagocytosis thus implicating the alternative complement pathway and CFB in pCD aetiology.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator B do Complemento / Doença de Crohn Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Gut Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Fator B do Complemento / Doença de Crohn Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies / Systematic_reviews Limite: Humans Idioma: En Revista: Gut Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Estados Unidos